In its latest cell and gene therapy effort, Bayer has agreed to partner with Atara Therapeutics for mesothelin-targeting chimeric antigen receptor T-cell therapies for the treatment of solid tumours. With the deal, which is worth up to US$675 M, Bayer gains access to Atara’s allogenic T-cell immunotherapy ATA3271 and its autologous version ATA2271. This deal complements Bayer’s August 2019 acquisition of BlueRock Therapeutics and Asklepios BioPharmaceutical in October 2020.